Introduction and Objective: Intensive weight loss can induce type 2 diabetes (T2D) remission, but implementing scalable, structured weight-loss programs within primary care is challenging. We assessed whether a digital behavior change program with coaching and a diabetes-specific nutritional formula (DSNF)-based low calorie diet (LCD) achieves T2D remission and improves other clinical outcomes at 1 year. Methods: RESET was a single-arm clinical program conducted across 28 UK primary care practices. Adults with T2D ≤6 years and body mass index (BMI) 27-45 kg/m² (N=185) entered a 12-week LCD phase (~900-1000 kcal/day) using DSNF as partial meal replacement or prescribed low-calorie foods, followed by 6-week food transition and 24-week maintenance phase. Glucose-lowering medications were stopped at enrollment. A digitally enabled self-management behaviour change intervention with coaching was provided. Outcomes included body weight, HbA1c, and blood pressure. Remission followed international consensus (HbA1c 48 mmol/mol 6.5% ≥6 months after start, no glucose-lowering drugs ≥3 months). Within-participant change from baseline (complete-case at 1 year) and remission rates were calculated. Results: At 1 year, 57% (105/185) of participants completed the program. Mean (±SD) weight change was −8.5 (±9.0) kg and HbA1c change was −7.1 (±13.2) mmol/mol (−0.7% ±1.2%, p0.001). Remission occurred in 35% of the participants (35/100 with required data), while 48% (49/102) had HbA1c 48 mmol/mol. Blood pressure improvements observed at 3 months were not significantly sustained at 12 months. Conclusion: A digital behavior change program with coaching and DSNF-based LCD was feasible in primary care and associated with significant weight loss maintenance and improved diabetes control at 1 year. Over one-third of participants achieved diabetes remission demonstrating the potential of structured, digital interventions to deliver sustainable outcomes in real-world practice. Disclosure M. Camprubi Robles: Employee; Current; Abbott. L.C. Taylor: Employee; Current; Changing Health Ltd. N. Northway: None. K. Kerr: Employee; Current; Abbott. C. Lumsden: None. L. Avery: None. D. Faluyi: None. S. Leathen: None. S.S. Sulo: Employee; Current; Abbott. R. Rueda: Employee; Current; Abbott. Funding Financial support for this study was provided by Abbott and UK Research and Innovation.
Robles et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: